Journal issues > Issue 2, March 2020 > Fertility preservation in women before cancer therapy

Fertility preservation in women before cancer therapy

SUMMARY

In recent decades, major progress has been made in cancer diagnosis and therapy, significantly extending the life expectancy of cancer patients and thereby dramatically increasing demand for fertility preservation. Indeed, of all cancers arising in women worldwide, ~15% occur in those aged <45 years, while ~40% of cancers affecting girls <20 years of age are of haematological origin. Furthermore, patients requiring chemotherapy and/or radiotherapy are at risk of premature ovarian failure. This review discusses different strategies aiming to preserve and protect fertility: embryo and oocyte cryopreservation; ovarian tissue cryopreservation; fertility-sparing surgery; gonadoprotective strategies; and new avenues of research like the artificial ovary and in vitro maturation of primordial follicles.

(BELG J HEMATOL 2020;11(2):44–8)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top